Gilead Sciences
Gilead Sciences
Gilead Sciences (pronounced: /ɡɪˈliːəd/), is an American biopharmaceutical company that researches, develops and commercializes innovative drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Etymology
The name "Gilead" comes from the Bible, where it is mentioned as a region in ancient Palestine known for its healing properties. The name was chosen to reflect the company's commitment to creating treatments and cures for diseases.
History
Gilead Sciences was founded in June 1987 by Michael L. Riordan, a medical doctor who was 29 years old at the time. The company's initial focus was on antiviral medicines, specifically those used to treat HIV and other infectious diseases.
Products
Gilead Sciences has developed and commercialized numerous products, most notably the antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. Some of the company's most well-known products include Truvada, Atripla, Complera, Stribild, Viread, Descovy, Odefsey, Genvoya, Biktarvy, Harvoni, and Sovaldi.
Research and Development
Gilead Sciences is heavily involved in research and development, with a focus on areas where medical needs are high and treatment options are limited. The company's research efforts are primarily focused on antiviral drugs, but it also has programs in other areas, such as respiratory diseases, oncology, inflammation, and cardiovascular diseases.
Controversies
Gilead Sciences has faced several controversies, particularly regarding the high prices of its antiviral drugs. The company has been criticized for pricing its hepatitis C drugs, Sovaldi and Harvoni, out of reach for many patients and healthcare systems.
External links
- Medical encyclopedia article on Gilead Sciences
- Wikipedia's article - Gilead Sciences
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski